- Trials with a EudraCT protocol (56)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
56 result(s) found for: Oropharyngeal Neoplasms.
Displaying page 1 of 3.
| EudraCT Number: 2011-005165-21 | Sponsor Protocol Number: RMRCT0034 | Start Date*: 2012-01-30 | |||||||||||
| Sponsor Name:University of Warwick | |||||||||||||
| Full Title: De-ESCALaTE HPV: Determination of Epidermal growth factor receptor-inhibitor (cetuximab) versus Standard Chemotherapy (cisplatin) early And Late Toxicity Events in Human Papillomavirus-positive oro... | |||||||||||||
| Medical condition: Human Papillomavirus oropharyngeal squamous cell carcinoma. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002360-14 | Sponsor Protocol Number: AK-2016-HHC1 | Start Date*: 2016-09-29 | ||||||||||||||||||||||||||
| Sponsor Name:Rigshospitalet, Dapartment of of Clinical Physiology, Nuclear Medicine and PET | ||||||||||||||||||||||||||||
| Full Title: Phase II trial: PET/CT for staging advanced and localized oral and oropharyngeal cancer | ||||||||||||||||||||||||||||
| Medical condition: Oral squamous cell cancer (OSCC) with and with out local metastasis Oropharyngeal squamous cell cancer (OPSCC) with and with out local metastasis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2022-001361-12 | Sponsor Protocol Number: FG001-CT-003 | Start Date*: 2022-08-25 | ||||||||||||||||
| Sponsor Name:FluoGuide A/S | ||||||||||||||||||
| Full Title: An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) for localization of oral and oropharyngeal squamous cell carcinoma | ||||||||||||||||||
| Medical condition: Oral and oropharyngeal squamous cell carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DK (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2019-001843-37 | Sponsor Protocol Number: 52649 | Start Date*: 2019-08-06 | ||||||||||||||||||||||||||
| Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
| Full Title: Imaging of tumour microenvironment in patients with oropharyngeal head and neck squamous cell carcinoma using RGD PET/CT imaging. | ||||||||||||||||||||||||||||
| Medical condition: The aim of this study is to assess differences in tumour microenvironment between HPV positive and HPV negative oropharyngeal head and neck squamous cell carcinoma using [68Ga]Ga-RGD2 PET/CT and p... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2014-003389-26 | Sponsor Protocol Number: RG14-093 | Start Date*: 2015-01-12 | |||||||||||
| Sponsor Name:University of Birmingham | |||||||||||||
| Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer | |||||||||||||
| Medical condition: Oropharyngeal Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Temporarily Halted) IE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-002244-16 | Sponsor Protocol Number: NRG-HN002 | Start Date*: 2016-09-12 | |||||||||||
| Sponsor Name:Irish Clinical Oncology Research Group CLG, trading as Cancer Trials Ireland | |||||||||||||
| Full Title: A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer | |||||||||||||
| Medical condition: Locoregionally advanced oropharyngeal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003392-32 | Sponsor Protocol Number: 2014/VCC/0014 | Start Date*: 2014-10-24 | |||||||||||
| Sponsor Name:Velindre NHS Trust | |||||||||||||
| Full Title: A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer | |||||||||||||
| Medical condition: Oropharyngeal cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003652-32 | Sponsor Protocol Number: ISA101b-OPC-03-19 | Start Date*: 2021-04-13 | |||||||||||
| Sponsor Name:ISA Therapeutics B.V. | |||||||||||||
| Full Title: A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16- positive Oropharyngeal Cancer who have experienced disease progres... | |||||||||||||
| Medical condition: Recurrent/metastatic HPV16- positive Oropharyngeal Cancer (OPC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) FR (Completed) BE (Completed) CZ (Completed) ES (Ongoing) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-002799-28 | Sponsor Protocol Number: TG4001.12 | Start Date*: 2020-03-19 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:Transgene | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of the he... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-004875-38 | Sponsor Protocol Number: PRIMEH&N | Start Date*: 2020-11-12 | |||||||||||||||||||||
| Sponsor Name:Fondazione GONO | |||||||||||||||||||||||
| Full Title: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
| Medical condition: HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-001077-87 | Sponsor Protocol Number: IJB-RT-HNC-001 | Start Date*: 2019-08-08 | |||||||||||
| Sponsor Name:Institut Jules Bordet | |||||||||||||
| Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t... | |||||||||||||
| Medical condition: advanced head and neck cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-004052-11 | Sponsor Protocol Number: UC-HNG/1909 | Start Date*: 2020-07-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:UNICANCER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Histologically or cytologically confirmed squamous cell carcinoma of the oral cavity, oropharynx, larynx or hypopharynx, previously untreated, with indication of primary surgery. Patients with a di... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2021-004277-31 | Sponsor Protocol Number: E012-HPV | Start Date*: 2021-12-23 | ||||||||||||||||||||||||||||||||||||
| Sponsor Name:eTheRNA immunotherapies NV | ||||||||||||||||||||||||||||||||||||||
| Full Title: A phase I/IIa open label study to assess the safety, tolerability, immunogenicity and clinical activity of EI-201 mRNA immunotherapy given intravenously in subjects with recurrent or metastatic HPV... | ||||||||||||||||||||||||||||||||||||||
| Medical condition: Incurable recurrent or metastatic (R/M) HPV16-positive (HPV16+) tumors (e.g. oropharyngeal cancer, cervical, vulvar, vaginal, anal, penile cancer, etc.) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
| Trial protocol: BE (Completed) DE (Completed) NL (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2019-003058-10 | Sponsor Protocol Number: NADEJ201901 | Start Date*: 2019-11-21 | |||||||||||
| Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s. | |||||||||||||
| Full Title: Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV) | |||||||||||||
| Medical condition: Human Papillomavirus oropharyngeal squamous cell carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2016-003934-25 | Sponsor Protocol Number: 3475-412 | Start Date*: 2017-03-20 | |||||||||||
| Sponsor Name:Merck Sharp & Dohme LLC | |||||||||||||
| Full Title: A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous... | |||||||||||||
| Medical condition: Locally advanced head and neck squamous cell carcinoma (LA HNSCC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) PL (Completed) CZ (Completed) BE (Completed) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-001456-21 | Sponsor Protocol Number: B9991016 | Start Date*: 2017-05-09 | |||||||||||
| Sponsor Name:Pfizer Inc. | |||||||||||||
| Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF AVELUMAB IN COMBINATION WITH STANDARD OF CARE CHEMORADIOTHERAPY (CISPLATIN PLUS DEFINITIVE RADIATION THERAPY) VERSUS STANDARD OF CARE CHEMORADIOTHERAPY IN... | |||||||||||||
| Medical condition: SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) BE (Prematurely Ended) DE (Prematurely Ended) PL (Completed) AT (Prematurely Ended) ES (Prematurely Ended) IE (Completed) PT (Prematurely Ended) HU (Prematurely Ended) FR (Completed) GR (Completed) IT (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-003226-33 | Sponsor Protocol Number: 0480 | Start Date*: 2018-09-13 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Dean of the Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg Prof. Dr. Markus Neurath | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8) | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Locally advanced head and neck squamous cell carcinoma (HNSCC) | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2015-003011-38 | Sponsor Protocol Number: 20130232 | Start Date*: 2016-02-29 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the He... | |||||||||||||
| Medical condition: Metastatic Squamous Cell Carcinoma of the Head and Neck | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) AT (Completed) ES (Completed) GR (Completed) DE (Prematurely Ended) PT (Completed) FR (Completed) PL (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-001731-55 | Sponsor Protocol Number: 106636 | Start Date*: 2007-08-09 | |||||||||||
| Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
| Full Title: A phase III/IV, community-randomized, controlled study to evaluate the effectiveness of two vaccination strategies using GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine in reducing the p... | |||||||||||||
| Medical condition: For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18. | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: FI (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2023-000183-65 | Sponsor Protocol Number: TTCC-2022-01-RADIAN | Start Date*: 2023-08-23 | |||||||||||
| Sponsor Name:Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC) | |||||||||||||
| Full Title: Phase Ib/II non-randomized non-comparative two-cohort study of Niraparib and Dostarlimab plus (Chemo)RadIotherapy in Locally-Advanced head and Neck squamous cell carcinoma (RADIAN) | |||||||||||||
| Medical condition: Locally-Advanced head and Neck squamous cell carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
